Latest turnover: 54,088,000
Three-year compound growth rate (%): 56.05
Latest EBITDA: 13,238,871
Established in Ireland in 1994, Flynn Pharma is a specialist pharmaceutical company focused on acquiring and commercialising branded products in secondary healthcare markets. The company was initially responsible for the distribution of a number of barbiturate products.
Since then, Flynn has acquired a range of oral and injectable antibiotics from Eli Lilly & Co and even created a hospital sales force and launched a Medikinet range for the treatment of ADHD.
In 2012, Flynn Pharma became the UK partner of Innocoll for the marketing and distribution of the CollaGUARD adhesion barrier.
The company says its goal is “to be the foremost European provider […] in the underserved therapeutic categories.”
Share this story